Showing 15 posts of 209 posts found.


Mylan to buy Renaissance’s dermatology business for up to $1 billion

May 16, 2016
Research and Development, Sales and Marketing Mylan, generics, merger and acquisition

Generics maker Mylan (Nasdaq: MYL) has agreed to buy skincare products from Renaissance Acquisition Holdings for up to $1 billion. …


Sun Pharma forays into Japan with $293 million product buy from Novartis

March 30, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Japan, M&A, MA, Novartis, Sun Pharma, generics

Shares of Sun Pharma (BOM: 524715), the largest Indian drug maker rose over 2% Wednesday as the company announced the …


Dr. Reddy’s, TR-Pharm to collaborate on 3 biosimilars in Turkey

March 11, 2016
Manufacturing and Production, Medical Communications, Sales and Marketing Dr Reddy's Laboratories, TR-Pharm, biosimilar, generics, marketing collaboration

Three biosimilar products by the Indian generics company Dr. Reddy’s will be marketed by TR-Pharm in Turkey, the companies said …


Lupin completes acquisition of US-based Gavis Pharmaceuticals

March 10, 2016
Research and Development, Sales and Marketing FDA, Gavis, Lupin, acquisition, generics

Indian drug manufacturer Lupin has announced the completion of its acquisition of New Jersey-based pharmaceutical firm, Gavis, in a deal …


US Federal Trade Commission clamps down on pharma ‘pay to delay’ deals

January 14, 2016
Manufacturing and Production, Sales and Marketing Pay to delay, US Supreme Court, antitrust laws, federal trade commission, generic competition, generics, patents, pay for delay

Pharma companies were able to negotiate far fewer so-called ‘pay to delay’ cases as a strategy to stave off generic …

Takeda and Teva set out generics joint venture plan

January 4, 2016
Sales and Marketing Takeda, Teva, generics, joint venture

Takeda and Teva have detailed plans for a new joint venture to create a new company to market off-patent generic …

Pills image

OTC drugs market boosted by growing patient demand

December 24, 2015
Manufacturing and Production, Sales and Marketing GBI Research, OTC, generics, over the counter

Increasing pressures from customers, drug manufacturers and regulators to convert prescription medications to over-the-counter (OTC) non-prescription status is driving growth …

Justice department

Mylan receives court summons from US Department of Justice

December 7, 2015
Sales and Marketing Drug pricing, Justice department, Mylan, US Department of Justice, generics, investigation, subpoena

The US Department of Justice has contacted Mylan to make enquiries about the company’s pricing structure for antibiotic, doxycycline. Mylan …

Beximco logo

FDA approves Beximco to manufacture Carvedilol for US

November 24, 2015
Manufacturing and Production Bangladesh, Beximco, Carvediol, FDA, exports, generics

Beximco Pharmaceuticals has become the first Bangladeshi pharma company to receive approval for a prescription drug to be manufactured in …


Global drug spending will rise 30% by 2020, to $1.4 trillion

November 18, 2015
Research and Development IMS Health, OTC, drug spending, emerging markets, generics, prescribing

Global spending on drugs will increase 30% to $1.4 trillion by 2020, as more patients get access to treatments and …

Europe Member State flags

EU plans export waiver for pharma manufacturing

November 3, 2015
Manufacturing and Production EGA, European Commission, biologics, biosimilars, generics, manufacturing, supplementary protection certificates

The European Commission plans to bring in an export waiver for supplementary protection certificates, in order to boost pharma industry …


ANALYSIS: The challenges of forecasting biosimilar sales across Europe

October 29, 2015
Manufacturing and Production, Research and Development, Sales and Marketing biologics, biosimilars, generics, patent cliff, patents, sales, sales forecasts

The introduction of biologic medicines revolutionised treatment in several key therapeutic areas, including oncology, diabetes and various inflammatory diseases.The landscape …

BGMA D-G Warwick Smith

OPINION: ‘More work remains if biosimilars are to fulfil their potential’

October 27, 2015
Manufacturing and Production, Research and Development, Sales and Marketing British Generic Manufacturers Association, NHS, bgma, biosimilars, generics, patent cliff, patents

Despite having a mature generics market which fulfils more than three-quarters of all prescriptions in the UK, and as a …


Future Focus: The industry’s top five biggest drug patent expirations in 2016

October 21, 2015
Manufacturing and Production, Research and Development biosimilars, blockbuster, generics, patent cliff, patents

From Humira to Cubicin, some multi-billion dollar drugs are set to be hit hard by patent expiries next year, and …

Daiichi Sankyo

Daiichi sheds more US jobs as generic losses take their toll

October 20, 2015
Daiichi, Daiichi Sankyo, generic competition, generics, job losses, patent cliff, patents, redundancies

The Japan-based drugmaker Daiichi Sankyo is to cut up to 1,200 jobs – or about half its workforce – in …

Latest content